The prevalence, severity, and risk factors of post-traumatic stress in patients with vitiligo is assessed.
The relationship between vitiligo and celiac disease is reviewed.
The sNDA submission included data from the phase 3 TRuE-V clinical trial program.
The application is supported by data from the phase 3 TRuE-V clinical trial program.
Less than half of women experiencing hair loss have genetic origins as the cause; possible causes and treatments are reviewed.
Results from both studies demonstrated that ruxolitinib met the primary endpoint with a greater proportion of patients achieving F-VASI75 at week 24.